MANAGEMENT TEAM
GREGG PETERSON / CHIEF EXECUTIVE OFFICER
Gregg has over 20 years in healthcare research and has developed pharmaceutical, biologic, medical device and combination products from ideation to product launch. He has extensive experience running Phase I-III clinical trials and his work has led to 20+ agency approvals and 11 product launches across the US, EU and AsiaPac. While at Allergan Gregg was the R&D Program Lead for a global product franchise. He is a veteran of multiple startup biotechnology companies and holds a B.S. from University of Puget Sound and a M.A. from the Medical College of Wisconsin.
JEFFREY BECKER, MD / CHIEF SCIENTIFIC OFFICER
Dr. Becker has over 20 years of research and clinical experience in NMDA-receptor pharmacology and clinical use. He is a world recognized speaker and expert in the clinical use of ketamine, and one of the first MDs in U.S. using ketamine for depression in the clinic. Jeff has also developed an effective nutraceutical product addressing NMDA-receptor abnormalities. He has an M.D. from UCLA and maintains a clinical practice focused in Functional Psychiatry and novel treatment approaches to mental health conditions.
CORPORATE ADVISORS
WILSON, SONSINI, GOODRICH & ROSATI - IP Attorneys
Led by partner Matthew Bresnahan, WSGR is preparing and filing Bexson’s patent applications, as well as counseling the company's IP strategy. The WSGR team has extensive experience helping life science and technology companies with all aspects of intellectual property, patent prosecution, licensing and litigation.
SCILUCENT - Regulatory Affairs & Toxicology Consulting Team
SciLucent’s team of consultants has vast experience developing innovative pharmaceuticals, medical devices, combination products and dietary supplement ingredients. Bexson is using SciLucent for their regulatory affairs, scientific and toxicology expertise.
IQVIA - Contract Research Organization
JASON WALLACH, PhD - Consultant, Medicinal Chemistry
IQVIA, formerly Quintiles, is another large CRO with global expertise across almost all R&D functions. Bexson is using IQVIA for our Orphan regulatory strategy and submissions. IQVIA’s Orphan Drug Unit was born from the 2017 acquisition of Coté Orphan, a specialty consulting firm founded by the former head of the Office of Orphan Products Development, Dr. Tim Coté. This group has arguably the best pedigree in orphan consulting in the industry, and their orphan designation applications have a >95% success rate.
Dr. Wallach has an appointment to the Substance Use Disorders Institute at University of the Sciences and an adjunct appointment at Cooper Medical School of Rowan University. He has over a decade of research experience with studying N-methyl-D-aspartate receptor (NMDAR) antagonists. Dr. Wallach’s research includes the chemistry and pharmacology of dissociative drugs including ketamine, and has published numerous peer-reviewed publications and book chapters. He focuses on the therapeutic potential of this drug class in neurological and psychiatric disorders. This work includes the design and synthesis of over 100 novel compounds and their investigation as NMDAR antagonists.
THOMAS ECKRICH, PD – Consultant, Chemistry Manufacturing & Controls
Dr. Eckrich provides expertise to Bexson Biomedical in the areas of process chemistry strategy, CMC, material and technology source development and source management. He received his PhD in Chemistry from Harvard University and worked for Eli Lilly and Company for 30 years before consulting.
CLINICAL ADVISORS
JOSEPH SHURMAN, MD
Dr. Shurman is an anesthesiologist and Chair of Pain Management at Scripps Memorial Hospital, La Jolla, CA. He is board certified in anesthesiology, a diplomate of the American Academy of Pain, a member of the California Society of Anesthesiologists Committee on Pain Medicine, and a former clinical assistant professor at the University of California, San Diego.
JOSHUA PRAGER, MD, MS
Dr. Prager is board-certified in anesthesiology, internal medicine and pain medicine, and director of the Center for the Rehabilitation of Pain Syndromes. He serves on the Faculty Executive Committee at the David Geffen School of Medicine at UCLA, past Chair of the CRPS Group for the International Association for the Study of Pain (IASP) and past President of the North American Neuromodulation Society.